Table 2. Correlation between KIF20A protein expression and the clinicopathologic features of patients with early-stage cervical squamous cell carcinoma.

Characteristic		Total	KIF20A		Chi-squared test P-value	Fisher’s exact test P-value
			No or weak expression	Moderate or strong expression
Age (years)	≤46	86	60 (35.5)	26 (15.4)	0.194	0.202
	>46	83	50 (29.6)	33 (19.5)
HPV infection	No	33	28 (16.6)	5 (3.0)	0.008	0.008
	Yes	136	82 (48.5)	54 (31.9)
FIGO stage	IB1	74	60 (35.5)	14 (8.3)	0.001	-
	IB2	25	16 (9.5)	9 (5.3)
	IIA1	52	25 (14.8)	27 (16.0)
	IIA2	18	9 (5.3)	9 (5.3)
Squamous cell carcinoma antigen (ng/ml)	≤1.5	80	58 (34.3)	22 (13.0)	0.055	0.075
	>1.5	89	52 (30.8)	37 (21.9)
Tumor size (cm)	<4	129	89 (52.7)	40 (23.7)	0.056	0.061
	≥4	40	21 (12.4)	19 (11.2)
Tumor recurrence	No	155	105 (62.1)	50 (29.6)	0.016	0.021
	Yes	14	5 (3.0)	9 (5.3)
Vital status (at last follow-up)	Alive	141	101 (59.8)	40 (23.7)	<0.001	<0.001
	Dead	28	9 (5.3)	19 (11.2)
Differentiation grade	G1	53	34 (20.1)	19 (11.2)	0.445	-
	G2	101	64 (37.9)	37 (21.9)
	G3	15	12 (7.1)	3 (1.8)
Chemotherapy	No	82	53 (31.4)	29 (17.2)	0.904	1.000
	Yes	87	57 (33.7)	30 (17.7)
Radiotherapy	No	162	106 (62.7)	56 (33.1)	0.652	0.696
	Yes	7	4 (2.4)	3 (1.8)
Concurrent chemotherapy and radiotherapy	No	153	101 (59.8)	52 (30.8)	0.436	0.425
	Yes	16	9 (5.3)	7 (4.1)
Myometrium invasion	<1/2	64	45 (26.6)	19 (11.2)	0.266	0.319
	≥1/2	105	65 (38.5)	40 (23.7)
Property of surgical margin	No	156	98 (58.0)	58 (34.3)	0.032	0.035
	Yes	13	12 (7.1)	1 (0.6)
Infiltration of parauterine organ	No	160	104 (61.5)	56 (33.1)	0.919	1.000
	Yes	9	6 (3.6)	3 (1.8)
Lymphovascular space involvement	No	142	98 (58.0)	44 (26.0)	0.014	0.026
	Yes	27	12 (7.1)	15 (8.9)
Pelvic lymph node metastasis	Absent	121	88 (52.1)	33 (19.5)	0.001	0.001
	Present	48	22 (13.0)	26 (15.4)